Recensa Therapeutics, Inc. has a new approach to treating psoriasis: topical therapies that reduce oxidative stress. Instead of modulating the immune system, Recensa’s Nrf2 Activators will leverage the body’s own antioxidants to stop the inflammatory cycle. Supported by the University City Science Center and using novel technology from Temple University, Recensa plans to be first-to-market with this new mechanism of action for the six million U.S. patients with mild-to-moderate psoriasis.
The Recensa team combines expertise in both the research and business sides of pharmaceuticals and biotechnology. We bring years of experience in industry and academia to the challenge of creating a better treatment for psoriasis.
Recensa is developing small molecules that activate the transcription factor Nrf2, a key modulator of antioxidant response. These molecules will be embedded in topical vehicles-such as creams or lotions-and will be tested in animal models of psoriasis so we can gain FDA approval for human clinical trials. Future products may target other diseases where oxidative stress is a key factor.
Year 1: Candidate selection
Year 2: IND-enabling studies
Year 3: Complete studies and file IND with the FDA
THE FIRST REGULATOR OF OXIDATIVE STRESS FOR THE TOPICAL TREATMENT OF PSORIASIS
ACTIVATING NRF2 WITHIN THE CELL:
-Stimulates the release of up to 300 anti-oxidants
-Targets psoriasis at the cellular level
-Can interrupt the inflammatory cycle
a bright future for nrf2-targeting therapies
NRF2 ACTIVATORS HAVE THE POTENTIAL TO:
-Alleviate symptoms with fewer systemic side effects
-Provide better solutions in order to increase patient satisfaction
SEEKS INTERESTED PARTNERS
Recensa Therapeutics is a growing company. We will need employees and corporate partners. If you want to join us in our goal to improve the lives of psoriasis patients by working with us or becoming a partner, please click the tab below.